Statutory Q2 revenue +23%
Statutory Q2 revenue +23%
Watch: Use matched financial periods and distinguish statutory consolidated amounts from management business divisions.
Home / Research / Gland Pharma Limited
Statutory Q2 revenue +23%
NSE integrated consolidated
Issuer Q2 presentation
Issuer Q2 presentation
Issuer Q2 presentation
Statutory Q2 revenue +23%
Watch: Use matched financial periods and distinguish statutory consolidated amounts from management business divisions.
Reported, not ESOP-adjusted
Watch: Use matched financial periods and distinguish statutory consolidated amounts from management business divisions.
Includes ESOP addback
Watch: Use matched financial periods and distinguish statutory consolidated amounts from management business divisions.
Derived from rounded reported figures
Watch: Use matched financial periods and distinguish statutory consolidated amounts from management business divisions.
Key takeaways
EBITDA means earnings before interest, taxes, depreciation and amortization; it is not cash flow. CDMO means contract development and manufacturing organization.
Gland Pharma reported Q2 FY27 consolidated revenue of ₹1,833.6 crore, 23% above ₹1,486.9 crore a year earlier. Reported EBITDA of ₹480.4 crore rose 53% from ₹313.9 crore, lifting the reported margin from approximately 21% to 26%.
Adjusted EBITDA was ₹503.0 crore, but that is not interchangeable with the reported figure: management adds back ₹22.6 crore of ESOP costs in the quarter. Consolidated PAT increased to ₹290.8 crore from ₹183.7 crore.
These are figures from the issuer's accepted 6 November investor presentation, in ₹ million divided by ten to express crore; the NSE consolidated revenue and PAT have now been reconciled to original integrated Ind-AS data.
Investment question: is the acceleration from durable sterile-injectable and CDMO volume/mix, or a quarter helped by regional launches and temporary facility timing? The two operating engines both grew: CDMO Q2 revenue was ₹822.7 crore versus ₹628.9 crore, a 31% increase, and critical injectables revenue was ₹1,010.9 crore versus ₹858.0 crore, up 18%.
Their sums match consolidated revenue in the issuer's management breakdown, reducing one source of segment-reconciliation uncertainty. CDMO contributed approximately 45% of Q2 revenue versus about 42% a year earlier.
This business-mix shift is an observable positive, not proof of higher cash returns without a working-capital and capex bridge.
Research stance: WATCH pending full original-page, forward-cash and valuation verification. Positive evidence includes broad Q2 growth, improved year-on-year operating leverage, a growing CDMO contribution and net cash. Principal uncertainties are Cenexi recovery, US FDA clearance for additional ready-to-use bag capacity, the timing of new technology-transfer programs, exchange-rate sensitivity, R&D and expansion spending, and whether the stronger H1 margin can be sustained. The stance is not investment advice.
Key takeaways
The issuer's Q2 presentation shows CDMO contribution at approximately 45% of total revenue and 47% for H1, a potentially material structural change if repeat contracts and regulatory compliance persist.
Management described commercial supply from previously signed contracts, new launches, technology transfers and expanded manufacturing agreements in microspheres and respiratory products. The distinction between contracts signed, transfers underway and commercial supply is central.
A technology-transfer dossier is not yet approved commercial revenue; manufacturing contracts need site readiness, regulatory clearance, customer qualification and volume ramp. No unsupported backlog amount is inferred from the pipeline.
The accepted 6 November earnings call describes broader global innovator interest but offers no reliable conversion rate from requests to cash receipts.
The critical injectables division recorded ₹1,010.9 crore in Q2, up 18% from ₹858.0 crore; H1 revenue was ₹1,919.7 crore versus ₹1,622.5 crore. The group launched four US products during Q2, including Sugammadex, Erythromycin, Fluorouracil and Atropine sulfate.
The issuer disclosed 11 ANDA filings and 10 approvals in the quarter, taking cumulative filings to 399 (350 approved and 49 pending). These measures indicate development and regulatory execution, but an approved ANDA is not a guarantee of commercial share, pricing or contribution margin.
The US generated ₹1,179.5 crore of Q2 sales, reportedly up 42% year-on-year, making US demand and concentration particularly relevant.
Cenexi is a critical operating risk rather than a detail to be blended away. Management reported approximately €41 million of Q2 Cenexi revenue and a €6 million EBITDA loss, primarily attributed to planned annual shutdowns.
It expected a return to profitability from Q3. That expectation is forward-looking, not a result. Cenexi profitability is also relevant to tax: management said its losses did not provide current or deferred tax relief, contributing to the consolidated effective Q2 tax rate near 33%.
A scenario that assumes Cenexi immediately breaks even must disclose the timing and tax assumptions separately.
Key takeaways
Units in the deck are ₹ million; divide by ten for ₹ crore. Q2 revenue ₹1,833.6 crore (Q2 FY26 ₹1,486.9 crore; Q1 FY27 ₹1,800.3 crore) and H1 revenue ₹3,633.9 crore (H1 FY26 ₹2,992.5 crore) provide an arithmetically consistent quarterly-to-half-year bridge: Q1 ₹1,800.3 crore plus Q2 ₹1,833.6 crore equals H1 ₹3,633.9 crore.
The adjusted measure adds ESOP expense and any one-off GST-related provision as defined in the deck. Q2 adjusted EBITDA was ₹503.0 crore versus ₹335.5 crore in Q2 FY26 and ₹510.2 crore in Q1 FY27. The Q2 difference between adjusted and reported EBITDA is ₹22.6 crore, matching management's Q2 ESOP add-back.
H1 adjusted EBITDA ₹1,013.2 crore versus reported ₹973.4 crore implies a ₹39.8 crore adjustment. An analyst cannot substitute adjusted EBITDA into EV/EBITDA while using a peer's reported denominator without explicit comparability adjustment.
Q2 profit before tax was ₹430.9 crore compared with ₹283.9 crore; consolidated PAT ₹290.8 crore compared with ₹183.7 crore. The Q2 effective tax burden implied by these two figures is approximately 32.5%.
Management attributed the elevated tax rate partly to Cenexi losses not qualifying for current/deferred tax benefit. H1 PBT ₹865.9 crore and PAT ₹607.7 crore imply a 29.8% effective rate. This matters for forecasts: a rebound in Cenexi's operating EBITDA could lower group tax drag, but that is a scenario until the next reported quarter confirms it.
Balance sheet: management disclosed cash and cash equivalents of ₹3,441.2 crore and net cash of ₹3,221.6 crore at 30 September 2026. The difference implies approximately ₹219.6 crore of borrowings under management's specified net-cash definition.
It is a derived difference, not a verified complete gross debt or lease schedule. The deck's net cash definition uses cash and equivalents less total borrowings including current maturities; it may differ from a valuation analyst's treatment of leases, deposits, restricted balances and minority interests.
Cash balances were ₹3,359.1 crore in FY26 and ₹3,115.7 crore in FY25; those are year-end reference points, not quarter-matched flow comparisons.
Cash-flow basis: the investor deck reports cash from operations of ₹602.7 crore for the six months ended September 2026. Its accompanying FY25 and FY26 CFO chart values ₹914.7 crore and ₹1,031.4 crore are full-year amounts, so plotting them as H1 FY25/H1 FY26 comparisons would be wrong.
The NSE consolidated H1 statement establishes investing cash outflow ₹188.29 crore and financing cash outflow ₹360.021 crore; original signed-page reconciliation of working capital and taxes remains pending. The consolidated H1 cash statement gives PPE purchases ₹254.177 crore and intangible purchases ₹2.91 crore.
CFO ₹602.738 crore less those cash purchases ₹257.087 crore equals ₹345.651 crore; this is a derived cash screen, not certified free cash flow. The planned capital expansion program, including vial, ophthalmic, BFS, liposomal, Vizag and Cenexi investments, means that CFO alone overstates immediately distributable cash.
The presentation reports net working capital of ₹2,485.5 crore at 6M FY27 versus ₹2,595.5 crore at FY26 and ₹2,168.3 crore at FY25, using current assets excluding cash/bank balances less current liabilities. Its cash-conversion-cycle metric improved from 164 days in FY26 to 158 days in H1 FY27.
This is a six-day improvement in the company's stated calculation, not proof that every working-capital account fell. Receivable days 123, inventory days 96 and payable days -61 sum to 158 days. The model must avoid mixing these days with annualized revenue or inventing a balance-sheet cash release without the signed cash statement.
Key takeaways
This is not a 15% reported-rupee guarantee, and it should not be presented as a raised outlook. The next checkpoint is the signed FY27 full-year result, with constant-currency translation methodology and actual reported growth shown separately.
The most consequential exchange concerned capex. An analyst asked about an earlier ₹2,000 crore program, the new brownfield investment and the planned Vizag greenfield. Management clarified that an additional ₹1,000 crore brownfield project had been approved, bringing the non-greenfield indicated program to approximately ₹3,000 crore, and estimated 300–400 million units of added capacity from that amount.
The separate greenfield project was at an earlier planning stage and its capex had not been formally announced; an analyst's hypothetical additional ₹2,000 crore should NOT be represented as an approved budget. The expected duration was roughly four years for greenfield and about two years to commercialize certain nearer-term brownfield contracts.
Future reported capital commitments, approvals and commissioning dates must be checked against this promise.
Management cited approximately 92% utilization in liquid vials and demand implying capacity requirements exceeding existing capacity next year. A projected 102% demand-to-capacity figure is not a physically achieved utilization rate; it is an indication of the need to expand or manage the order book.
This distinction matters to valuation: the upside case has credible demand pressure, but new manufacturing lines have construction, validation, inspection, ramp and depreciation costs before commercial cash arrives. The brownfield plan may address a near-term constraint more rapidly than Vizag, while the longer greenfield build can depress cash returns for years if volumes disappoint.
A question about microsphere contracts revealed three signed projects, including one exhibit batch already taken, with development and technology-transfer revenue initially and royalty-based commercial revenues anticipated after FY2029–30. The size of the future royalties was not disclosed.
Therefore the institutional model must not place a fabricated FY27 or FY28 recurring royalty stream into near-term EBITDA. Management's references to GLP-1 and other complex injectable launches are pipeline indicators until the product, customer, regulatory approval, timing and commercialization economics are actually confirmed.
Cenexi's transformation is another measurable management promise. The company said the business generated approximately €41 million Q2 revenue and a €6 million EBITDA loss during planned annual shutdowns.
The chairman emphasized profitability and cost reduction rather than maximizing top-line growth, including workforce efficiency and faster manufacturing lines. He expected an operating improvement after the shutdown quarter.
This is a reasonable operational plan but not yet a demonstrated turnaround. The next results should separately show Cenexi EBITDA, shutdown normalization, utilization and any restructuring costs; a consolidated tax-rate benefit from fewer Cenexi losses is contingent on actual results.
Promise-to-actual ledger for future quarters: (1) 15% constant-currency FY27 growth versus realized comparable results; (2) sustainability of US launch/CDMO demand versus actual regional revenue; (3) Cenexi return to profitability versus separately disclosed operating EBITDA; (4) approved ₹3,000 crore non-greenfield capex and 300–400 million capacity versus actual expenditure and commissioning; (5) later greenfield budget only when formally announced; (6) microsphere commercial royalties only after verified regulatory and commercial milestones. These are management claims, not completed investment facts.
Key takeaways
Net cash ₹3,221.6 crore is management-defined and should not automatically be treated as freely distributable excess cash.
A transparent sensitivity can use a deliberately hypothetical EBITDA range of ₹1,654.8 crore (15% below the doubled-H1 reference), ₹1,946.8 crore base, and ₹2,238.8 crore (15% above). If illustrative EV/EBITDA multiples of 15x, 20x and 25x are applied, resulting enterprise values are approximately ₹24,822 crore, ₹38,936 crore and ₹55,970 crore.
These multiples are analyst stress assumptions, NOT observed peer multiples or certified targets. Under an unchanged ₹3,221.6 crore management-defined net-cash assumption, corresponding simplified equity remainders would be approximately ₹28,044 crore, ₹42,158 crore and ₹59,192 crore, before minority, lease, other debt and restricted-cash adjustments.
No per-share target is issued until the share count is signed and verified.
Key takeaways
The unannounced greenfield capex amount is an uncertainty, not an analyst-certified commitment.
The downside is concentrated in FDA and other regulator inspections, sterile manufacturing quality, launch competition and pricing, long project validation periods, capacity construction and higher cash consumption, foreign-exchange volatility, and Cenexi's European fixed-cost base. A second-order risk is that cash on the balance sheet is treated as permanently excess while the company has approved substantial multi-year capex.
The ₹3,000 crore non-greenfield indicated program and an unquantified greenfield project should be monitored against actual financing, commissioning and utilization. A forecast that ignores these cash costs would overstate shareholder value.
Quarterly decision triggers should compare consolidated revenue with ₹1,833.6 crore, reported EBITDA with ₹480.4 crore, adjusted EBITDA with ₹503.0 crore, PAT with ₹290.8 crore and net cash with ₹3,221.6 crore, all on the same reporting perimeter and date basis. Check whether US sales of ₹1,179.5 crore remain supported by product launches and whether Cenexi returns from a €6 million quarterly EBITDA loss.
The 158-day cash conversion cycle and ₹602.7 crore H1 CFO are useful baselines but not substitutes for signed capex and cash-flow statements. A genuine upgrade needs consistent margins and cash after investment; a deterioration in regulatory status or site economics would weaken the thesis.
Key takeaways
Monetary values in the presentation are rupee millions, converted to crore by division by ten. Its content is used as numerical evidence, not reproduced wholesale.
S2 — Accepted issuer earnings-call transcript, filed 12 November 2026 for the 6 November call: issuer document, SHA-256 a8d5bbc3c3fbfedede265d88a30f15afaf31ecbeda8eaf50e0c52ff68dd077c0. Issuer investor-relations page:
It supports management's constant-currency guidance, capital commitments, Cenexi operating discussion, and project commercialization timing. Both canonical documents were previously accepted and scored using full-window FinBERT; unchanged content has not been re-extracted or rescored.
S3 — Original statutory results now located: 6 November NSE signed Board outcome https://nsearchives.nseindia.com/corporate/GLAND_06112026162953_OutcomeBMQ2FY27_Final.pdf and consolidated integrated Ind-AS https://nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_INDAS_211616_06112026221234_iXBRL_WEB.html. Q2 revenue ₹1,833.588 crore, PAT ₹290.756 crore, EPS ₹17.62; H1 CFO ₹602.738 crore, cash asset purchases ₹257.087 crore. Independent signed-page, standalone, lease/minority and PIT QA remains open.
S4 — Market observation: 16 November 2026 close ₹3,385.90 from Sage's NSE_BHAVCOPY_FALLBACK reference; it is dated context, not an independently verified execution price. Share count, leases, minority interest, restricted cash, market capitalization and observed peer multiples remain unverified. The valuation cases above are illustrative enterprise-value sensitivities and must not be marketed as price targets or advice.
Publication and rights: original analytical commentary and derived tables may be retained privately. The issuer presentation expressly restricts reproduction or quotation without prior written approval, so the published product must avoid reproducing source passages and must preserve source attribution internally.
No full institutional QA approval is claimed. The seven-chapter manuscript and 22 source-labelled charts pass structural checks, but independent signed-page and standalone reconciliation, PIT and rights review, lease/minority/peer valuation checks and sanctioned publication QA remain open.
No public edition or independent QA certification is asserted.
NSE integrated consolidated
Issuer Q2 presentation
Issuer Q2 presentation
Issuer Q2 presentation
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.